EGFR and glioblastoma: Three glioblastoma patients (P05, P07, and P17) with EGFR exon2–7 deletion, EGFR amplification, and TERT promoter variants in the brain tumor tissue received neoadjuvant or adjuvant chemoradiotherapy.